Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsGUANGZHOU, China & MOSCOW--(BUSINESS WIRE)--Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has reached a licensing...
GUANGZHOU, China--(BUSINESS WIRE "BAT1706 is the company's second application for marketing approval of a Biosimilar in China, following the approval of Qletli® (adalimumab injection)," said Dr. Li Shengfeng, founder and CEO of Bio-TheraSolutions. "L...
GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company, today announced that the Phase III clinical trial comparing the safety and efficacy of BAT1706 versus Avastin®1 (bevacizumab) met its primary endpoi...
